Provided by Tiger Trade Technology Pte. Ltd.

Cadrenal Therapeutics, Inc.

1.57
-0.0400-2.48%
Post-market: 1.570.00000.00%16:10 EDT
Volume:36.24K
Turnover:57.21K
Market Cap:5.60M
PE:-0.32
High:1.69
Open:1.69
Low:1.54
Close:1.61
52wk High:14.64
52wk Low:1.54
Shares:3.57M
Float Shares:3.14M
Volume Ratio:0.66
T/O Rate:1.15%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.8667
EPS(LYR):-6.6394
ROE:-275.16%
ROA:-125.93%
PB:1.37
PE(LYR):-0.24

Loading ...

Cadrenal Therapeutics - Appoints Quang X. Pham as Interim CFO and Interim Principal Accounting Officer - SEC Filing

THOMSON REUTERS
·
Jun 04

Cadrenal Therapeutics - Matthew K. Szot Steps Down as CFO Effective May 28, 2026 - SEC Filing

THOMSON REUTERS
·
Jun 04

Cadrenal Therapeutics names CEO Quang X. Pham interim CFO after Matthew Szot exit

Reuters
·
Jun 04

Cadrenal Therapeutics to attend BIO International Convention 2026 partnering event

Reuters
·
Jun 03

Cadrenal Therapeutics CEO, Chairman Quang X. Pham sells USD 3,057.57 in common shares

Reuters
·
Jun 03

Cadrenal Therapeutics CEO, Chairman Quang X. Pham sells USD 69,363 of common shares

Reuters
·
May 30

Cadrenal Therapeutics CEO, Chairman Quang Pham sells 1,165 common shares for $6,628.85

Reuters
·
May 27

Cadrenal Therapeutics to present at Lytham Partners Spring 2026 Investor Conference

Reuters
·
May 20

Cadrenal Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 08

Press Release: Cadrenal Therapeutics Reports First Quarter 2026 Financial Results and Provides Phase 3 Development Update on CAD-1005 Following End-of-Phase 2 Meeting with FDA

Dow Jones
·
May 07

Cadrenal Therapeutics Inc expected to post a loss of $1.62 a share - Earnings Preview

Reuters
·
May 04

Analysts’ Top Healthcare Picks: Pacira Pharmaceuticals (PCRX), Cadrenal Therapeutics, Inc. (CVKD)

TIPRANKS
·
May 01

Cadrenal Therapeutics completes CAD-1005 End-of-Phase 2 meeting with FDA

TIPRANKS
·
Apr 30

Cadrenal plans pivotal Phase 3 trial of CAD-1005 in heparin-induced thrombocytopenia

Reuters
·
Apr 30

Cadrenal Therapeutics Inc - FDA Provides Guidance for Phase 3 Advancement of CAD-1005 in Hit

THOMSON REUTERS
·
Apr 30

Cadrenal Therapeutics Inc - to Advance Directly to Phase 3 Study of CAD-1005 in Hit

THOMSON REUTERS
·
Apr 30

Cadrenal Therapeutics Announces End-of-Phase 2 Meeting With the FDA and Pivotal Phase 3 Registration Path for CAD-1005 in Heparin-Induced Thrombocytopenia (Hit)

THOMSON REUTERS
·
Apr 30

Cadrenal Therapeutics Inc - Phase 2 Data Shows >25% Absolute Reduction in Thrombotic Events With CAD-1005

THOMSON REUTERS
·
Apr 30

BRIEF-Cadrenal Therapeutics Inc - Prospectus Filed For Resale Of Up To 1.2 Million Shares Of Common Stock By Selling Stockholders- SEC Filing

Reuters
·
Apr 21

Cadrenal Therapeutics files to sell 1.18M shares of common stock for holders

TIPRANKS
·
Apr 21